Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human neuregulin in chronic systolic heart failure (Phase III)
CTR20201128Phase 3Completed
- Sponsor
- Zensun
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of neucardin in heart failure with reduced ejection fraction (HFrEF), sponsored by Zensun. Started Jun 2020; status: completed.
02
Drugs
neucardin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on CTR20201128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201128.